Board of Directors

Prof. Revel is Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. His research on Interferon, its mechanisms of action and the isolation of the human Interferon-beta gene, have led to the development of Interferon-beta therapy for the treatment of multiple sclerosis, Rebif®, Blockbuster drug marketed worldwide.

In recent years, Prof. Revel's laboratory focused on hESC and succeeded to produce nerve myelinating cells that, when transplanted in myelin-deficient animals, have regenerated the myelin coating. These studies contributed to the development of a suspension culture technology for hESC which can then be used to produce differentiated human cells such as insulin-producing pancreatic beta cells and nerve myelinating cells.

Alongside his research and development activity, Prof. Revel is deeply involved in the ethics of science and biotechnology, and serves as chairman of the Israel National Bioethics Council, and was a member of the International Bioethics Committee of UNESCO.

Prof. Revel was the recipient of the Israel Prize for medical research, the EMET Prize for biotechnology, and is a member of the Israel Academy of Science and Humanities. He has been a member of Israel's National Committee for Biotechnology, serving for three years as its chairman.

Mr. Ronen Twito serves as Executive Charmian and President of Kadimastem, having joined the company in December 2020. Under his leadership, he successfully repositioned the company's strategic direction, establishing Kadimastem as an emerging global leader in the cell therapy industry. Mr. Twito brings over two decades of executive leadership experience in the biotech and high-tech sectors, with a distinguished track record of driving corporate growth and maximizing shareholder value across both Nasdaq and Tel Aviv Stock Exchange listed companies.

Throughout his career, Mr. Twito has demonstrated exceptional expertise in corporate finance and strategic leadership, successfully orchestrating multiple IPOs, follow-on offerings, and high-value strategic licensing and collaboration agreements within the clinical biotech sector. His executive tenure includes pivotal roles as Deputy CEO and CFO at XTL Biopharmaceuticals (XTLB), Chief Executive Officer at Intercure Ltd, Executive Chairman at Bubbles Intergroup Ltd (BBLS), Deputy CEO and CFO at Cellect Biotechnology (APOP), External Director at MTS (MTSL), and VP Finance and Head of Israel Operations at BioBlast Pharma (ORPN). Earlier in his career, he served as Corporate Finance Director at LeadCom Integrated Solutions, a global company traded on London's AIM market, and as Manager at Ernst & Young.

Mr. Twito is a Certified Public Accountant (CPA) in Israel and holds a bachelor's degree in Business Administration and Accounting. He maintains active membership in the Institute of Certified Public Accountants in Israel.

Mr. Olivier  Samuel has been running consulting activity since 2001, in operational and strategic project management specialized in the field of health, in particular in the fields of geriatric care and healthcare management on behalf of leading operators and brands in the field of medical equipment, retirement homes, telecommunication operators, health insurance and investment funds.  

He has been a member of the board of Kadimastem since 2010 on behalf of Mr Julien Ruggierie. Since 2020 Olivier has been serving as a board member of Kadimastem.

Mr. Samuel is a graduate of EM Lyon and the Lille School of Health Engineers.  

Mr. Samuel was the CEO from 1997 to 2020 was the CEO of Adomsante in France, a company specialized in home care and medical equipment for the elderly in France. 

Mr. Iohan brings with him over 20 years of financial, accounting, and managerial experience. Mr. Iohan served as CFO of Turbogen Ltd. (TURB.TA) and led its IPO on TASE. Prior to that Mr. Iohan served for more than 12 years as Partner at PwC Israel. Leading IPOs, follow-on investments, and complex transaction in Israel and US for technology and bio-technology companies.

Eran is a Certified Public Accountant (CPA), Israel and US (California). He has a B.A. in Accounting and Economics, and an MBA in Finance and Information Technologies, both from the Tel-Aviv University.

Liora Oren brings with her 20 years of financial experience in various companies including the Bio-Tech Industry, and multinational companies traded on the NYSE and the NASDAQ.

Liora is a Certified Public Accountant (CPA), in Israel, She holds a B.A. in accounting and economics from Tel-Aviv University and M.A. in law from Bar-Ilan University.

Tammy Galili is the CEO of Ilex Medical Ltd., since 2016. Ilex Medical Ltd. is a leading company in the medical diagnostics industry. Ms. Galili has more than three decades of experience in various positions at Ilex Medical, including VP of Operations, HR Manager and Quality Control Manager. Her more recent positions were Deputy CEO from 2014 to 2016 and VP of Sales & Marketing in 2010. Ms. Galili is one of 4 female CEO’s in the TA-125 index, also chosen as one of the Top Best CEO’s in Israel in 2020 by Calcalist Magazine. She has a MBA in Healthcare Innovation from Reichman University in Herzliya and a BA in Philosophy and History of the Middle East in Modern Times from Tel Aviv University.